Catalyst Wire Dossier Catalyst Wire Dossier

low-dose recombinant human thrombopoietin

rhTPO
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for low-dose recombinant human thrombopoietin, covering 2022-12-02 to 2022-12-02. Get the full timeline:

Most recent: Clinical Trial Update: IVIg Plus Low Dose rhTPO for ITP in Pregnancy [Phase 2]

See pricing